Abstract
Background Lowering low-density lipoprotein cholesterol (LDL-C) through PCSK9 inhibition represents a new therapeutic approach to preventing and treating cardiovascular disease (CVD). Phenome-wide analyses of PCSK9 genetic variants in large prospective biobanks can help to identify unexpected effects of PCSK9 inhibition.
Methods The prospective China Kadoorie Biobank genotyped >100,000 participants with follow-up for fatal and non-fatal disease events. A PCSK9 genetic score (PCSK9-GS) was constructed using three single nucleotide polypmorphisms at the PCSK9 locus associated with directly-measured LDL-C, including a loss-of-function variant (rs151193009). Logistic regression gave estimated odds ratios (ORs) for PCSK9-GS associations with CVD and non-CVD outcomes, scaled to 1-standard deviation (SD) lower LDL-C.
Results PCSK9-GS was associated with lower apolipoprotein B, and with lower risks of carotid plaque (n=8340 cases; OR=0.61 [95%CI: 0.45-0.83]; P=0.0015), major occlusive vascular events (n=15,752; 0.80 [0.67-0.95]; P=0.011), and ischaemic stroke (n=11,467; 0.80 [0.66-0.98]; P=0.029). However, PCSK9-GS was also associated with higher risk of hospitalisation with chronic obstructive pulmonary disease (COPD: n=6836; 1.38 [1.08-1.76]; P=0.0089), and with even higher risk of fatal exacerbations among individuals with pre-existing COPD (n=730; 3.61 [1.71-7.60]; P=7.3×10−4). Risk of acute upper respiratory tract infection (URTI) was also increased (n=1,095; 2.18 [1.34-3.53]; P=0.0016), as previously reported in UK Biobank, with a pooled OR after meta-analysis of 1.87 ([1.38-2.54]; P=5.4×10−5). We also replicated a previously-reported association with self-reported asthma (pooled OR 1.17 ([1.04-1.30]; P=0.0071). There was heterogeneity between the associations of PCSK9-GS and a polygenic LDL-C score for each of COPD hospitalisation (P-het=0.015), fatal COPD exacerbation (P-het=0.0012), and URTI (P-het=0.013).
Conclusions LDL-C-lowering PCSK9 genetic variants are associated with lower risk of subclinical and clinical atherosclerotic vascular disease, but higher risks of respiratory diseases which appear unrelated to LDL-C. Pharmacovigilance studies may be required to monitor patients treated with therapeutic PCSK9 inhibitors for exacerbations of respiratory diseases or respiratory tract infections.
Competing Interest Statement
The Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford (CTSU) is co-ordinating a PCSK9 phase III cardiovascular outcome trial (ORION 4). MVH has collaborated with Boehringer Ingelheim in research, and in accordance with the policy of CTSU did not accept any personal payment. MVH was at the University of Oxford when this work was conducted, and is presently employed by 23andMe and holds stock in 23andMe.
Funding Statement
The CKB baseline survey and the first re-survey were supported by the Kadoorie Charitable Foundation in Hong Kong. Long-term follow-up was supported by the Wellcome Trust (212946/Z/18/Z, 202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z), the National Natural Science Foundation of China (82192900, 81941018, 91843302, 91846303), and the National Key Research and Development Program of China (2016YFC0900500, 2016YFC0900501, 2016YFC0900504, 2016YFC1303904). DNA extraction and genotyping was funded by GlaxoSmithKline, and the UK Medical Research Council (MC-PC-13049, MC-PC-14135). The project is supported by core funding from the UK Medical Research Council (MC_UU_00017/1, MC_UU_12026/2, MC_U137686851), Cancer Research UK (C16077/A29186; C500/A16896), and the British Heart Foundation (CH/1996001/9454) to the Clinical Trial Service Unit and Epidemiological Studies Unit and to the MRC Population Health Research Unit at Oxford University. MVH was supported by a British Heart Foundation Intermediate Clinical Research Fellowship (FS/18/23/33512) and the National Institute for Health Research Oxford Biomedical Research Centre. MDT was partially supported through the National Institute for Health and Care Research (NIHR, Leicester Biomedical Research Centre and NIHR Senior Investigator Award). Views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. MDT was also supported via Wellcome Trust Awards WT202849/Z/16/Z and WT225221/Z/22/Z. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided written informed consent at each survey visit, allowing access to their medical records and long-term storage of biosamples for future unspecified medical research purposes, without any feedback of results to the individuals concerned. Oxford Tropical Research Ethics Committee of University of Oxford, the Ethical Review Committee of the Chinese Centre for Disease Control and Prevention of the Chinese Academy of Medical Sciences, and the Ethical Review Committee of the Institutional Review Board at Peking University, gave ethical approval for this work. The Chinese Ministry of Health approved the study at the start in 2004, and also approved electronic linkage to health insurance records in 2011.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵# Joint senior authors
